Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Compare

244 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KYMR Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Kymera

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$60.50

▲(24.49%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $60.50 with a high forecast of $79.00 and a low forecast of $51.00. The average price target represents a 24.49% change from the last price of $48.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","38":"$38","52":"$52","66":"$66","80":"$80"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$51.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,38,52,66,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.13,45.88923076923077,48.64846153846154,51.40769230769231,54.16692307692308,56.926153846153845,59.68538461538462,62.44461538461539,65.20384615384616,67.96307692307693,70.7223076923077,73.48153846153846,76.24076923076923,{"y":79,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.13,44.46615384615385,45.80230769230769,47.13846153846154,48.47461538461539,49.81076923076923,51.14692307692308,52.48307692307692,53.81923076923077,55.15538461538462,56.49153846153846,57.82769230769231,59.16384615384615,{"y":60.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.13,43.73538461538462,44.34076923076923,44.94615384615385,45.55153846153846,46.15692307692308,46.762307692307694,47.36769230769231,47.973076923076924,48.57846153846154,49.183846153846154,49.78923076923077,50.394615384615385,{"y":51,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.11,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.36,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.57,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$79.00

Average Price Target$60.50

Lowest Price Target$51.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$50

Hold

2.88%

Upside

Reiterated

06/07/25

Kymera Therapeutics' overall stock score reflects a mix of strong technical indicators and promising corporate developments, tempered by financial challenges. The company's robust pipeline and strategic focus on high-value programs enhance its future potential, despite current profitability issues.

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$43.13→$68

Buy

39.92%

Upside

Reiterated

06/09/25

Kymera Therapeutics (KYMR) Gets a Buy from Stifel Nicolaus

Faisal KhurshidLeerink Partners

Leerink Partners

$60

Buy

23.46%

Upside

Reiterated

06/03/25

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), CSPC Pharmaceutical Group (CHJTF)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$54

Buy

11.11%

Upside

Reiterated

06/03/25

Kymera Therapeutics' KT-621 Shows Promising Trial Results, Supporting Buy Rating

Kalpit PatelB.Riley Financial

B.Riley Financial

$38→$60

Buy

23.46%

Upside

Upgraded

06/03/25

Kymera Therapeutics upgraded to Buy from Neutral at B. RileyKymera Therapeutics upgraded to Buy from Neutral at B. Riley

Vikram PurohitMorgan Stanley

Morgan Stanley

$49→$79

Buy

62.55%

Upside

Upgraded

06/03/25

Kymera Therapeutics' KT-621 Shows Promising Potential, Upgraded to Overweight with $79 Target

Eliana MerleUBS

UBS

$70

Buy

44.03%

Upside

Reiterated

06/03/25

UBS Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Michael SchmidtGuggenheim

Guggenheim

$52→$60

Buy

23.46%

Upside

Reiterated

06/02/25

Kymera Therapeutics price target raised to $60 from $52 at GuggenheimKymera Therapeutics price target raised to $60 from $52 at Guggenheim

Derek ArchilaWells Fargo

Wells Fargo

$57

Buy

17.28%

Upside

Assigned

06/02/25

Analysts' Top Healthcare Picks: Genmab (GMAB), Omnicell (OMCL)

Eric JosephJ.P. Morgan

J.P. Morgan

$57→$64

Buy

31.69%

Upside

Reiterated

06/02/25

Kymera Therapeutics price target raised to $64 from $57 at JPMorganKymera Therapeutics price target raised to $64 from $57 at JPMorgan

Geoff MeachamCiti

Citi

$52→$60

Buy

23.46%

Upside

Reiterated

06/02/25

Citi Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

Jeet MukherjeeBTIG

BTIG

$55

Buy

13.17%

Upside

Reiterated

06/02/25

Promising Potential of Kymera Therapeutics' KT-621: Strong Therapeutic Effect and Buy Rating Affirmed

Srikripa DevarakondaTruist Financial

Truist Financial

$53

Buy

9.05%

Upside

Reiterated

06/02/25

Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)

Tazeen AhmadBank of America Securities

Bank of America Securities

$44→$51

Buy

4.94%

Upside

Upgraded

06/02/25

Kymera Therapeutics upgraded to Buy from Neutral at BofAKymera Therapeutics upgraded to Buy from Neutral at BofA

Jeff JonesOppenheimer

Oppenheimer

$56

Buy

15.23%

Upside

Reiterated

05/12/25

Kymera Therapeutics (KYMR) Receives a Buy from Oppenheimer

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$50

Hold

2.88%

Upside

Reiterated

06/07/25

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$43.13→$68

Buy

39.92%

Upside

Reiterated

06/09/25

Kymera Therapeutics (KYMR) Gets a Buy from Stifel Nicolaus

Faisal KhurshidLeerink Partners

Leerink Partners

$60

Buy

23.46%

Upside

Reiterated

06/03/25

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), CSPC Pharmaceutical Group (CHJTF)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$54

Buy

11.11%

Upside

Reiterated

06/03/25

Kymera Therapeutics' KT-621 Shows Promising Trial Results, Supporting Buy Rating

Kalpit PatelB.Riley Financial

B.Riley Financial

$38→$60

Buy

23.46%

Upside

Upgraded

06/03/25

Kymera Therapeutics upgraded to Buy from Neutral at B. RileyKymera Therapeutics upgraded to Buy from Neutral at B. Riley

Vikram PurohitMorgan Stanley

Morgan Stanley

$49→$79

Buy

62.55%

Upside

Upgraded

06/03/25

Kymera Therapeutics' KT-621 Shows Promising Potential, Upgraded to Overweight with $79 Target

Eliana MerleUBS

UBS

$70

Buy

44.03%

Upside

Reiterated

06/03/25

UBS Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Michael SchmidtGuggenheim

Guggenheim

$52→$60

Buy

23.46%

Upside

Reiterated

06/02/25

Kymera Therapeutics price target raised to $60 from $52 at GuggenheimKymera Therapeutics price target raised to $60 from $52 at Guggenheim

Derek ArchilaWells Fargo

Wells Fargo

$57

Buy

17.28%

Upside

Assigned

06/02/25

Analysts' Top Healthcare Picks: Genmab (GMAB), Omnicell (OMCL)

Eric JosephJ.P. Morgan

J.P. Morgan

$57→$64

Buy

31.69%

Upside

Reiterated

06/02/25

Kymera Therapeutics price target raised to $64 from $57 at JPMorganKymera Therapeutics price target raised to $64 from $57 at JPMorgan

Geoff MeachamCiti

Citi

$52→$60

Buy

23.46%

Upside

Reiterated

06/02/25

Citi Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

Jeet MukherjeeBTIG

BTIG

$55

Buy

13.17%

Upside

Reiterated

06/02/25

Promising Potential of Kymera Therapeutics' KT-621: Strong Therapeutic Effect and Buy Rating Affirmed

Srikripa DevarakondaTruist Financial

Truist Financial

$53

Buy

9.05%

Upside

Reiterated

06/02/25

Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)

Tazeen AhmadBank of America Securities

Bank of America Securities

$44→$51

Buy

4.94%

Upside

Upgraded

06/02/25

Kymera Therapeutics upgraded to Buy from Neutral at BofAKymera Therapeutics upgraded to Buy from Neutral at BofA

Jeff JonesOppenheimer

Oppenheimer

$56

Buy

15.23%

Upside

Reiterated

05/12/25

Kymera Therapeutics (KYMR) Receives a Buy from Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

1 Month

xxx

Success Rate

7/11 ratings generated profit

Average Return

+11.34%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +11.34% per trade.

3 Months

xxx

Success Rate

8/12 ratings generated profit

Average Return

+24.97%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +24.97% per trade.

1 Year

Faisal KhurshidLeerink Partners

Success Rate

8/9 ratings generated profit

Average Return

+32.02%

reiterated a buy rating 10 days ago

Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +32.02% per trade.

2 Years

xxx

Success Rate

13/13 ratings generated profit

Average Return

+60.70%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KYMR has received 26 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 60.50.

Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

Next quarter’s earnings estimate for KYMR is -$0.84 with a range of -$1.08 to -$0.17. The previous quarter’s EPS was -$0.82. KYMR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year KYMR has Outperformed its overall industry.

KYMR Sales Forecast

Next quarter’s sales forecast for KYMR is $17.38M with a range of $0.00 to $55.10M. The previous quarter’s sales results were $22.10M. KYMR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year KYMR has Outperformed its overall industry.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Kymera Therapeutics’s 12-month average price target is 60.50.

What is KYMR’s upside potential, based on the analysts’ average price target?

Kymera Therapeutics has 24.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KYMR a Buy, Sell or Hold?

Kymera Therapeutics has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kymera Therapeutics’s price target?

The average price target for Kymera Therapeutics is 60.50. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $51.00. The average price target represents 24.49% Increase from the current price of $48.6.

What do analysts say about Kymera Therapeutics?

Kymera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of KYMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

KYMR Analyst Ratings

KYMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kymera Therapeutics

KYMR Analyst Recommendation Trends

KYMR Financial Forecast

KYMR Earnings Forecast

KYMR Sales Forecast

KYMR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts